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Cancer-associated inﬂammation develops resistance to the epidermal growth-factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) in non-small cell lung cancers (NSCLCs) harboring oncogenic EGFR
mutations. Stat3-mediated interleukin (IL)-6 signaling and Smad-mediated transforming growth factor-b
(TGF-b) signaling pathways play crucial regulatory roles in cancer-associated inﬂammation. However,
mechanisms how these pathways regulate sensitivity and resistance to EGFR-TKI in NSCLCs remain
largely undetermined. Here we show that signal transducer and activator of transcription (Stat)3 re-
presses Smad3 in synergy with the potent negative regulators of TGF-b signaling, c-Ski and SnoN,
whereby renders geﬁtinib-sensitive HCC827 cells resistant. We found that IL-6 signaling via phosphor-
ylated Stat3 induced geﬁtinib resistance as repressing transcription of Smad3, whereas TGF-b enhanced
geﬁtinib sensitivity as activating transcription of Smad3 in HCC827 cells with geﬁtinib-sensitizing EGFR
mutation. Promoter analyses showed that Stat3 synergized with c-Ski/SnoN to repress Smad2/3/4-
induced transcription of the Smad3 gene. Smad3 was found to be an apoptosis inducer, which upregu-
lated pro-apoptotic genes such as caspase-3 and downregulated anti-apoptotic genes such as Bcl-2. Our
results suggest that derepression of Smad3 can be a therapeutic strategy to prevent geﬁtinib-resistance
in NSCLCs with geﬁtinib-sensitizing EGFR mutation.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Although EGFR-TKIs have remarkably improved the therapeutic
efﬁcacy for NSCLCs harboring the sensitive EGFRmutation [1], drug
resistance inevitably develops [2]. Genetic changes such as sec-
ondary mutations in EGFR (T790M) and ampliﬁcation of the MET
receptor tyrosine kinase are the mainmechanisms of acquired drugr Pathology, Tokyo Medical
60-8402, Japan; Biomedical
Hospital, 50 SAMDUK-2GA,
1 6141; fax: þ81 3 3351 6173.
c.jp, mikoeyo@gmail.com
Inc. This is an open access article uresistance [3,4]. Unknown mechanisms of EGFR-TKI resistance in
the remaining cases [4] could be attributed to chronic inﬂamma-
tion, which plays critical roles in tumorigenesis [5]. It is also
possible that chronic inﬂammatory responses induce DNA damages
and mutations [6].
IL-6 is the pivotal pro-inﬂammatory cytokine in inﬂammation
including cancer-associated inﬂammation [7,8], which affects
treatment effectiveness [9]. IL-6 and EGF share Stat3 for their
signaling pathways, which promote carcinogenesis through
inﬂammation [10,11]. In NSCLCs, correlation between elevation of
IL-6 and phosphorylation of Stat3 are signiﬁcantly correlated
[12,13].
In contrast with IL-6, TGF-b is the principal immunosuppressive
cytokine secreted in the tumormicroenvironment [14]. Elevation of
TGF-b is frequently observed in NSCLCs, which is correlated withnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Smads mediate the canonical pathway for signal transduction from
the TGF-b receptor (TbR) serine threonine kinases. Activated TbRI
phosphorylates serine residues in MH2 domains of receptor-
regulated Smads (R-Smads), Smad2 and Smad3, which oligo-
merize with the common-mediator Smad, Smad4 to regulate
transcription of the target genes [16,17]. Smad2 and Smad3 are
highly homologous molecules with distinct effects in context-
dependent manners, however, detailed mechanisms of involve-
ment of Smad2 versus Smad3 in carcinogenesis remains largely
undetermined [18].
Transmodulation between the STAT and SMAD signaling path-
ways has been implicated as the basis for the antagonism between
TGF-b and pro-inﬂammatory cytokines such as interferon-g, IL-1b
and TNF-a [19,20]. It has been reported that TGF-b-dependent IL-6
secretion and subsequent Stat3 activation induce EGFR-TKI resis-
tance in NSCLCs [21]. We previously reported that Smad2 and
Smad3 oppositely regulate Th17 differentiation as Stat3 cofactors
[22]. However, the mechanisms whether and how Stat3-mediated
IL-6 signaling and Smad-mediated TGF-b signaling interact to
regulate EGFR-TKI resistance in NSCLCs remain largely unknown.
In this study, we examined the mechanisms how R-Smads and
Stat3 regulate the sensitivity and resistance to geﬁtinib in HCC827
lung adenocarcinoma cells with geﬁtinib-sensitizing EGFR
mutation.
2. Materials and methods
2.1. Cell culture and transfection
Human lung adenocarcinoma HCC827 cells (ATCC) were
cultured in RPMI 1640 (Hyclone) supplemented with 10% heat-
inactivated FBS (Gibco) and 1% penicillin/streptomycin (Thermo-
Scientiﬁc) with or without the combinations of human IL-6 (R&D,
10 ng/ml), TGF-b1 (R&D, 5 ng/ml) and geﬁtinib (AstraZeneca, 2 mM)
for 4 h after serum starvation and grown at 37 C with 5% CO2. No
mutations or copy number variations of TGF-b signaling molecules
are observed in HCC827 cells (http://cancer.sanger.ac.uk/cell_lines/
sample/overview?id¼1240146). HCC827 cells were seeded a day
before transfection and transfected with Smad3 cDNA, Smad3
siRNA, Stat3 siRNA or control siRNA (GE Dharmacon) using Lip-
ofectamine LTX & Plus Reagent (Invitrogen) following manufac-
ture's protocol as previously described [22].
2.2. Cell cycle analysis
DNA content was determined by propidium iodide (PI; BD
Pharmingen). Brieﬂy, HCC827 cells were ﬁxed by cold 80% ethanol
overnight at 20 C, washed twice with phosphate-buffered saline
(PBS) containing 1% bovine serum albumin (BSA), and then resus-
pended in PI solution in PBS containing RNase A (0.1 mg/ml; Sigma-
Aldrich). Stained samples were acquired by FACSCalibur (BD
Bioscience) and analyzed by FlowJo (Tree Star).2.3. Immunocytochemistry
Proximity ligation assay (PLA) was performed as previously
described [22]. HCC827 cells were ﬁxed with 4% formaldehyde.
Fixed slides were permeabilized by 0.1% Triton X-100 in PBS for
staining with Duolink in situ PLA probes anti-rabbit PLUS and PLA
probe anti-rabbit MINUS or PLA probe anti-mouse PLUS and PLA
probe anti-mouse MINUS and detection reagents (Sigma-Aldrich),
rabbit or mouse antibodies against Smad2, Smad3, phospho-Stat3
Y705, phospho-Stat3 S727 (Cell Signaling Technology), Stat3, c-
Ski and SnoN (Santa Cruz). Nucleus was stained with DAPI. Slides
were observed using a confocal microscope, LSM700 (Carl Zeiss).
PLA signals were quantiﬁed using BlobFinder software (http://
www.cb.uu.se/~amin/BlobFinder/).
2.4. RNA isolation and quantitative RT-PCR
Total RNA was extracted from HCC827 cells using Trizol ac-
cording to the manufacturer's instructions (Invitrogen). RNA was
reverse transcribed with a cDNA RT kit (Invitrogen). Human cDNA
was quantitated by SYBR green (Applied Biosystems) using ABI
7900 (Applied Biosystems). Each experiment was performed in
triplicate. The following primers were used: GAPDH 50- CTCAA-
GACCTTGGGCTGGG-30, 50-TCGAACAGGAGGAGCAGAGA-30, Smad3
50-GAGTTGAGGCGAAGTTTGGG-30, 50-AGTGAAAGGCAGGATGGACG-
30, Bcl2 50-AACATCGCCCTGTGGATGAC-30, 50-CAGGGCCAAACTGAG-
CAGAG-30, Bbc3 50-ACTCACCAAACCAGAGCAGG-30, 50-ACAAAT
CTGGCAGGGGACC-30, Bnipl 50-AACCAGCTCCCCAACAACTC-30, 50-
ATGTCTCAGGGCTGCTCCTA-30, Caspase2 50-CTTGCTGCCTAAGAGG
GGTC-30, 50- CTCACACACCGGAAAAGGGA-30, Caspase3 50-CTCTGGT
TTTCGGTGGGTGT-30, 50-TCCAGAGTCCATTGATTCGCT-30, Cidec3 50-
CAGAGCCAGGGGATGAGAAA-30, 50-CACAGAGGTACGCACT
GACA-30
2.5. Luciferase reporter assay
The 2000 bp promoter region of Smad3 was generated by PCR
from genomic DNA using the primers: 50-GATCACGCGTTTGGGTT-
CAAATTCCAGCTC-30 and 50-GATCCTCGAGGCAGCAGAAGTTTGGGTT
TC-30. The product was veriﬁed by sequencing and was subcloned
into pGL3 Basic ﬁreﬂy luciferase construct (Promega) using Mlu1
and XhoI sites. The promoter construct was transfected in various
combination with Stat3, Flag-tagged Stat3Y705F, Stat3 S727A
(Addgene, submitted by J. Darnell), Flag-tagged Smad2/3/4, Flag-
tagged c-Ski, SnoN, TGIF or empty pcDNA3 plasmid in
HCC827 cells using Lipofectamine (Invitrogen). Twenty-four hours
after transfection, HCC827 cells were lysed using lysis buffer for the
measurement using luciferase assay kit (Promega) by luminometer.
Each experiment was performed in triplicate.
2.6. Chromatin immunoprecipitation (ChIP)
Chromatin was prepared from HCC827 cells. Immunoprecipi-
tation was performed with antibodies against Smad2, Smad3, tri-
methyl histone H3 Lys4 and tri-methyl histone H3 Lys27 (Cell
Signaling Technology), Smad4, c-Ski, SnoN and STAT3 (Santa Cruz)
using ChIP kit (Cell Signaling Technology) according to the manu-
facturer's protocol. Immunoprecipitated DNA released from the
cross-linked proteins was quantitated by real time PCR using the
primers: 1700 to 1534 50-AATGCCAAGTAAGGCACAGG-30 50-
CTCCCTTCCACTTGCTGCTA-30, 1559 to 1410 50-TCTCTAGCAG-
CAAGTGGAAGG-30 50-GCAGCTTGTCAGGGGTTGT-30, 1196
to 1003 50-TAGCCTGATAGGGAGGCTGA-30 50-CCGGAGAGGACTC
GAGAAGT-30, 524 to 372 50-GAGCTTTTCTGAACCCCTCA-30 50-AC
CGGACTCCTGGGGACT-30, 220 to 28 50-
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to þ63 50-CAGAGGAGGAGGAGGAGGAG-30 50-CGA-
GACTCCAAGTGGCAGTAG-30 and was normalized to input DNA.
Each experiment was performed in triplicate.
3. Results
3.1. Stat3-mediated IL-6 signaling induces geﬁtinib resistance in
HCC827 lung adenocarcinoma cells
We used HCC827 lung adenocarcinoma cells with EGFR746E-
750A deletion to examine the mechanisms how IL-6 and its
downstream Stat3 signaling induce geﬁtinib resistance in this
study. TGF-b and geﬁtinib induced apoptosis with synergistic pro-
apoptotic effect, whereas IL-6 suppressed TGF-b/geﬁtinib-induced
apoptosis (Fig. 1A). IL-6 enhanced phosphorylation of Stat3 at
tyrosine 705 (pY705) and serine 727 (pS727), whereas TGF-b and
geﬁtinib suppressed Stat3 phosphorylation (Fig. 1B). Consistent
with the previous report [23], we conﬁrmed that Stat3 deletion by
RNAi accelerated, whereas Stat3 overexpression inhibited TGF-b/
geﬁtinib-induced apoptosis (Fig. 1C, Supplementary Fig. 1). Thus,
Stat3-mediated IL-6 signaling induced resistance to TGF-b/geﬁtinib
in HCC827 cells.
3.2. Stat3-mediated IL-6 signaling represses Smad3 in HCC827 cells
Wenext examined the status of TGF-b receptor-regulated Smads
(R-Smads), Smad2 and Smad3 in HCC827 cells treated with TGF-b
and geﬁtinib with or without IL-6. We found that IL-6 abolished the
expression of Smad3 protein, whereas Smad2 remained expressed
(Fig. 2A). IL-6 completely inhibited the expression of Smad3 mRNA
(Fig. 2B), indicating that IL-6 repressed the transcription of the
Smad3 gene. By contrast, TGF-b and geﬁtinib upregulated Smad3
mRNA (Fig. 2B). Luciferase reporter spanning 2 kilobase upstream
of the ﬁrst exons of the Smad3 genes showed that IL-6 repressed,
whereas TGF-b and geﬁnitib induced the Smad3 gene promoter
activity (Fig. 2C). Canonical TGF-b signaling molecules, R-Smads:
Smad2/3 and common Smad: Smad4 synergistically induced the
Smad3 gene promoter activity (Fig. 2D). By contrast, Stat3 repressed
the Smad3/4-induced Smad3 gene promoter activity (Fig. 2E).
Consistently with the phosphorylation status of Stat3 (Fig. 1B) and
the expression levels of Smad3 (Fig. 2A), Stat3 mutations at Y705 or
S727 completely abolished this repression (Fig. 2E), indicating that
Stat3 phosphorylation at Y705 and S727 is essential for Stat3-
induced repression of the Smad3 gene. Overexpression of Stat3
signiﬁcantly suppressed, whereas Stat3 knockdown upregulated
the expression of Smad3 protein in HCC827 cells (Fig. 2F). These
results show that Smad-mediated TGF-b signaling induces,
whereas Stat3-mediated IL-6 signaling represses the transcription
of the Smad3 gene.
3.3. c-Ski and SnoN cooperate with Stat3 to repress Smad3
We sought to determine how Stat3 represses the Smad3 gene.
We screened the representative Smad co-repressors: Ski/SnoN and
TGIF [17,24e26] for Stat3 co-repressors, and found that c-Ski and
SnoN, but not TGIF showed synergy with Stat3 to repress the
Smad3/4-induced Smad3 gene promoter activity (Fig. 3A). c-Ski and
SnoN are the potent negative regulators of TGF-b signaling [24e26].
ChIP showed that Smad2/3/4 were bound to the same site in the
Smad3 promoter (1700 to1534) upon TGF-b stimulation (Fig. 3B,
middle), which was epigenetically active with methylated histone
H3 lysine 4 (Fig. 3C, left). By contrast, Stat3, c-Ski and SnoN were
bound to the Smad3 promoter (1559 to 1410), overlapped or
proximal to the Smad2/3/4 biding site upon IL-6 stimulation(Fig. 3B, lower), which was epigenetically inactive with trimethy-
lated histone H3 lysine 27 (Fig. 3C, right). PLA showed that TGF-b
inhibited, whereas IL-6 enhanced the interactions between Stat3
and c-Ski/SnoN (Fig. 3D) in accordance with Stat3 phosphorylation
status (Fig. 1B). These results indicate that phosphorylated Stat3
cooperates with c-Ski and SnoN to repress Smad-induced tran-
scription of the Smad3 gene.
3.4. Smad3 induces apoptosis and restores IL-6-induced geﬁtinib
resistance
We examined the physiological relevance of IL-6/Stat3-induced
repression of Smad3 to geﬁtinib resistance by overexpression or
knockdown of Smad3 in HCC827 cells. Forced expression of Smad3
signiﬁcantly induced, whereas knockdown of Smad3 by RNAi
signiﬁcantly inhibited spontaneous and geﬁtinib/TGF-b-induced
apoptosis of HCC827 cells (Fig. 4A). IL-6-induced geﬁtinib resis-
tance was completely abolished by forced expression of Smad3
(Fig. 4A, right third row). Smad3 overexpression upregulated pro-
apoptotic genes such as Caspase3, Caspase2 and Cidec (cell death-
inducing DNA fragmentation factor-like effector c), while
repressed anti-apoptotic genes such as Bcl2 (b-cell leukemia/lym-
phoma 2 protein), Bbc3 (BCL2 Binding Component 3) and Bnipl
(BCL2 Interacting Protein Like) (Fig. 4B). By contrast, Smad3
knockdown showed the opposing patterns (Fig. 4B). These data
show that Smad3 enhances geﬁtinib/TGF-b-induced apoptosis and
restores IL-6-induced geﬁtinib resistance by upregulating pro-
apoptotic genes and downregulating anti-apoptotic genes in
HCC827 cells.
4. Discussion
Variousmechanisms lead to inevitable development of EGFR TKI
resistance including the secondary mutations to a drug-resistant
state, activation of alternative signaling pathways, impairment of
EGFR-TKI-mediated apoptosis and histologic transformation or
epithelial-mesenchymal transition (EMT) [27]. Chronic inﬂamma-
tory responses in tumor microenvironment not only induce drug
resistance but also induce DNA damages and mutations [6,21,23].
Thus, it is important to investigate the inﬂammatory mechanisms
to induce EGFR TKI resistance. The representative pro-
inﬂammatory cytokine in cancer-associated inﬂammation, IL-6 is
the potent inducer of EGFR TKI resistance in NSCLCs [23]. TGF-b is
essential for erlotinib resistance, EMT and increased activation of
IL-6 axis in resistant H1650 cells [21]. Unlike resistant NSCLCs, TGF-
b exerted synergistic pro-apoptotic effect with geﬁtinib in case of
highly EGFR TKI-sensitive HCC827 cells [28], in which both TGF-b
and geﬁtinib suppressed Stat3 phosphorylation at Y705 and S727 in
the absence of IL-6. The most signiﬁcant difference between highly
EGFR TKI-sensitive HCC827 cells and resistant NSCLC cell lines is IL-
6-induced repression of Smad3 in HCC827 cells. By contrast, Smad3
remained expressed and highly phosphorylated in resistant
H1650 cells with augmented IL-6 secretion [23]. It has been re-
ported that high expression of Smad3 and proﬁlin-2 is linked to
poor survival rate in lung cancer patients [29]. Because TGF-b
switches from tumor suppressor at early stages of carcinogenesis to
pro-oncogene at later stages of disease leading to metastasis [16],
our ﬁndings suggest that combined anti-inﬂammatory therapies
with EGFR-TKI at early stages may prevent cancer progression.
Although aberrant TGF-b signaling such as the mutations/
deletion of Smad4 and the TGF-b type II receptor is frequent in
cancers, the mutations/deletion of Smad2 and Smad3 are rarely
found [30]. Loss of Smad2 or Smad3 by post-transcriptional mod-
ulations has been reported in various cancers [18]. However, pre-
cise molecular mechanisms how their expression is selectively
Fig. 1. IL-6 and STAT3 render HCC827 adenocarcinoma cells geﬁtinib-resistant. (A) HCC827 cells were treated with various combinations of geﬁtinib, IL-6 and TGF-b. (B) STAT3
phosphorylated at Y705 or S727 was detected by PLA. Signals were quantiﬁed using BlobFinder software (scale bars: 10 mm, nucleus: black, cytoplasm: white, n ¼ 10 ﬁelds). Data are
mean þ s.d. (C) HCC827 cells were transfected with STAT3 cDNA, STAT3 siRNA or control siRNA and treated with various combinations of geﬁtinib, IL-6 and TGF-b. DNA contents
were determined by PI staining using ﬂowcytometry (A, C). Data are representative of three independent experiments.
Fig. 2. STAT3-mediated IL-6 signaling represses Smad3 in HCC827 adenocarcinoma cells. HCC827 cells were treated with geﬁtinib and TGF-b in the presence or absence of IL-6. (A)
Expression of Smad2 and Smad3 proteins in HCC827 cells was determined by PLA. (B) The expression of Smad3 mRNA relative to GAPDH in HCC827 cells was determined by
quantitative RT-PCR. (C) HCC827 cells transfected with the Smad3 promoter reporter construct were treated with geﬁtinib and TGF-b in the presence or absence of IL-6. (D)
HCC827 cells were transfected with the Smad3 promoter reporter construct with the indicated combinations of Smad2, Smad3 and Smad4. (E) HCC827 cells were transfected with
the Smad3 promoter reporter construct with the indicated combinations of Smad3, Smad4, STAT3, STAT3 mutants: Y705F or S727A. Fireﬂy luciferase activity was measured with a
luminometer and normalized to b-galactosidase activity. Each experiment was performed in triplicate. (F) Smad3 protein in HCC827 cells transfected with STAT3 cDNA, STAT3 siRNA
or control siRNA was detected by PLA. Signals were quantiﬁed using BlobFinder software (scale bars: 10 mm, nucleus: black, cytoplasm: white, n ¼ 10 ﬁelds). Data are mean þ s.d.
Data are representative of three independent experiments.
Fig. 3. Phosphorylated STAT3 represses the transcription of the Smad3 gene in synergy with c-Ski and SnoN. (A) HCC827 cells were transfected with the Smad3 promoter reporter
construct with the indicated combinations of Smad3, Smad4, STAT3, c-Ski, SnoN and TGIF. Fireﬂy luciferase activity was measured with a luminometer and normalized to b-
galactosidase activity. Bindings of Smad2/3/4, STAT3, c-Ski and SnoN to (B) the Smad3 proximal promoter region and (C) trimethylated histone H3 Lys4 (H3K4me3) and trime-
thylated histone H3 Lys 27 (H3K27me3) in HCC827 cells were determined by ChIP. Each experiment was performed in triplicate. (D) Protein interactions between STAT3 and c-Ski,
STAT3 and SnoN in HCC827 cells treated with or without TGF-b or IL-6 were detected by PLA. Signals were quantiﬁed using BlobFinder software (scale bars: 10 mm, nucleus: black,
cytoplasm: white, n ¼ 10 ﬁelds). Data are mean þ s.d. Data are representative of three independent experiments.
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Smads could be one of the mechanisms to distinguish their distinct
functions [18]. Smad3 is downregulated through decreased tran-
scription in lung epithelial cells [31] or through decreased gene
activation as well as increased protein degradation in glomerular
mesangial cells [32]. Here, we show that IL-6-Stat3 signaling re-
presses transcription of Smad3, thereby inducing geﬁtinib/TGF-b
resistance in HCC827 cells. Similar and synergistic effect of geﬁtinib
with TGF-b on HCC827 cells might be attributed to induction of
TGF-b by geﬁtinib [33]. Pro-inﬂammatory cytokine signaling
pathways antagonize TGF-b through upregulation of inhibitory
Smad, Smad7 [19,20]. Recent report shows that direct crosstalkFig. 4. Smad3 enhances geﬁtinib-induced apoptosis of HCC827 cells. (A) HCC827 cells were t
with or without TGF-b or IL-6. DNA contents were determined by PI staining using ﬂowcy
relative to GAPDH in HCC827 cells transfected with Smad3 cDNA, Smad3 siRNA or contro
triplicate. Data are mean þ s.d. Data are representative of three independent experiments.between Stat3 and Smad3 antagonizes TGF-b [34]. Ski and the
closely related SnoN are oncogenes, which act as transcriptional co-
repressors in TGF-b signaling through interaction with Smads
[24e26]. We show that c-Ski/SnoN cooperate with Stat3 to antag-
onize TGF-b by repressing Smad2/3/4-induced transcription of the
Smad3 gene. Future studies are required to clarify the relevance of
repression of Smad3 to the interactions of c-Ski/SnoN, Stat3 and
Smads in inﬂammation and carcinogenesis.
Stat3 activated through IL-6/JAK1 promotes cell survival and
erlotinib resistance in EGFR-addicted NSCLC cell lines [23]. TGF-b
also plays pivotal roles in cell survival [16e18]. Smad3 sensitizes
hepatocytes to apoptosis through down-regulation of Bcl-2 [35] orransfected with Smad3 cDNA, Smad3 siRNA or control siRNA and treated with geﬁtinib
tometry. (B) The expression of Caspase2, Caspase3, Cidec, Bcl2, Bbc3 and Bnipl mRNA
l siRNA was determined by quantitative RT-PCR. Each experiment was performed in
Y. Makino et al. / Biochemical and Biophysical Research Communications 484 (2017) 269e277276through cleavage of Bcl-2-associated death promoter (BAD) protein
[36]. TGF-b/Smad3 induces apoptosis through inducing and acti-
vating caspase-3 [37]. Our ﬁndings that Smad3 signiﬁcantly pre-
vented IL-6-induced geﬁtinib resistance in HCC827 cells as
upregulating caspase3 and downregulating Bcl2 are consistent
with these previous reports. Stat3 also targets similar set of
apoptosis-related genes [38]. Involvement of crosstalk between
Smads and Stat3 in regulation of apoptosis in IL-6-induced geﬁtinib
resistance is yet to be determined.
In summary, present study elucidated the novel mechanism
how IL-6/Stat3 induce geﬁtinib resistance in highly sensitive
HCC827 cells. IL-6 enhanced phosphorylation of Stat3 at Y705 and
S727, which interacted with the Ski family of proto-oncoproteins, c-
Ski and SnoN to repress Smad2/3/4-induced transcription of the
Smad3 gene. Repression of Smad3 resulted in resistance to
geﬁtinib-induced apoptosis, whereas forced expression of Smad3
restored IL-6-induced geﬁtinib resistance. Smad3 induced
apoptosis by upregulating pro-apoptotic genes as downregulating
anti-apoptotic genes. Our ﬁndings suggest that derepression of
Smad3might prevent inﬂammation-induced geﬁtinib-resistance at
early stages of NSCLCs with geﬁtinib-sensitizing EGFR mutation
while they retain sensitivity to tumor suppressor effects of TGF-b.
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